<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

KRASmut Ex Vivo Screen

Advance your KRAS-pathway therapeutic programs with 14 clinically relevant, low-passage ex vivo models derived from colorectal, pancreatic, and NSCLC tumors.

Enrolling until September 30th, 2025

 

 

Accelerate Your KRAS Drug Discovery with Clinically Relevant Ex Vivo Models

Champions Oncology’s KRASm Ex Vivo Screen provides access to a curated panel of patient-derived tumor models carrying clinically relevant KRAS mutations, including G12C, G12D, G12V, G12A, and G13D. These low-passage models are derived from our highly annotated PDX bank, offering unparalleled translational relevance for preclinical research.

14 Clinically Relevant Models

A curated panel of low-passage ex vivo models derived from patient tumors with key KRAS mutations for superior translational relevance.

Flexible, High-Throughput Screening

Available in both 96-well and 384-well plate formats, enabling efficient screening of multiple test agents per run.

Molecularly Annotated, Data-Rich Outputs

Each model includes comprehensive clinical annotations, molecular datasets, and CellTiter-Glo endpoints to inform actionable insights.

Champions' KRASmut Ex Vivo Screen features a curated panel of low-passage, patient-derived models carrying key KRAS mutations and clinical annotations. These models reflect clinically relevant characteristics and are optimized for ex vivo proliferation.

  • Includes models suitable for evaluating agents targeting KRAS-mutant pathways and those resistant to targeted therapies and immunotherapies.
  • Accelerated turnaround times, data delivery within 7 weeks
  • Comprehensive model characterization provided, including clinical data, NGS analysis, and additional molecular datasets.
  • Multiple endpoint data options available, such as CellTiter-Glo, with the option to collect samples for further analyses.
  • No minimum enrollment required, and one Standard of Care Agent (RMC-6236) is included in each screen.
KRASmut Ex Vivo Screen Models

Our screen includes 14 models across colorectal, pancreatic, and NSCLC indications. Each model is annotated with KRAS mutation status and optimized for ex vivo proliferation.

Model ID
Cancer Type
KRAS Mutation
CTG-0061
Colorectal
G12D
CTG-0064
Colorectal
G12V
CTG-0083
Colorectal
G12V
CTG-0654
Colorectal
G12D
CTG-0796
Colorectal
G12A
CTG-1885
NSCLC
G12V
CTG-2026
NSCLC
G12C
CTG-2536
NSCLC
G12C
CTG-2803
NSCLC
G12D
CTG-0286
Pancreatic
G12D
CTG-0492
Pancreatic
G12V
CTG-0955
Pancreatic
G12D
CTG-1150
Pancreatic
Q61R
CTG-2205
Pancreatic
G12V

Get Started Today

Contact our team to secure your place in the KRASm Ex Vivo Screen and accelerate your KRAS-targeted drug discovery.